California State Controller's Office

The strategic plan focuses on transforming communities, empowering families and individuals, and strengthening businesses through fiscal oversight and transparency. It emphasizes values such as honesty, integrity, accountability, equity, and inclusion. Key strategic initiatives revolve around people, processes, technology, and infrastructure, including employee incentives, workforce development, process automation, technology modernization, and infrastructure simplification.

The meeting included updates on the California Institute for Regenerative Medicine (CIRM)'s strategic plan, program changes, clinical trials, grants awarded, and future plans. A status update on CIRM's financial performance and budget was also presented, along with information on the 2019/20 Performance Audit and the CIRM Audit Response for 2020/21 Audit. The meeting also covered the 2020/21 Independent Financial Audit, CIRM's audit response, and State Controller's Audit Review Reports for 2020/21. Finally, an update on CIRM's Performance Audit was provided.

The meeting agenda includes an oath of office for a new member, a presentation of the 2009-10 Independent Financial Audit, a CIRM financial performance status update, a presentation of CIRM's "Report of the External Advisory Panel", a discussion of SB 1064/Alquist, Chapter 637, and consideration of the next meeting's draft agenda.

CIRM's strategic plan focuses on advancing world-class science through funding pillars encompassing discovery, translation, clinical research, education, and infrastructure. Key initiatives include de-risking programs, serving as a resource for both non-profit and for-profit sectors, bridging the valley of death, creating a manufacturing network, expanding access to clinical trials through partnerships, and fostering diversity, equity, and inclusion. Outcomes include significant investments in various disease areas, support for numerous clinical trials, development of a manufacturing network, and training programs to build a diverse workforce. A commitment to diversity, equity, and inclusion is central to the plan, with efforts to improve representation in clinical trials and education programs.

The meeting agenda includes presentations on the 2007-08 Independent Financial Audit, a status update on the California Institute for Regenerative Medicine's (CIRM) financial performance and grants, and the third annual report of the Citizens Financial Accountability Oversight Committee. The committee will also consider the draft agenda for the next meeting and allow for public comment.